AstraZeneca rises after $2 billion equity investment in Summit Therapeutics
29/09/2026 08:11
BUZZ-AstraZeneca rises after $2 billion equity investment in Summit Therapeutics ** Shares of AstraZeneca AZN.L up 1.5% at £126.8
** Company makes a $2 billion equity investment in Summit Therapeutics through convertible preferred shares
** Investment is convertible into Summit common stock at $18.36 per share, representing an 18.6% premium to its last closing price
** Analysts at Jefferies said AZN's equity investment in SMMT and global clinical trial deal are strategically smart, giving its oncology ADC portfolio a clear route to PD-1xVEGF combinations
** As of last close, AZN down ~9.5% YTD
(Reporting by Atharva Singh in Bengaluru)
Recent news on AstraZeneca
See all newsBrief: Abu Dhabi Biobank Partners With Astrazeneca To Advance Predictive Healthcare - AD Media Office
UK Stocks-Factors to watch on October 22 (updated)
Brief: AstraZeneca Says Ultomiris Approved In Us In IgAN
Ultomiris approved in US in IgAN
AstraZeneca says FDA approves drug for rare kidney disease in adults